Introduction
Acute myeloid leukemia (AML) is associated with high rates of relapse and mortality and despite aggressive treatments such as hematopoietic cell transplantation (HCT) many patients fail to achieve long-term survival. Attempts to decrease relapse after HCT have, among other approaches, utilized intensified cytoreductive therapies either by increasing total body irradiation (TBI) or doses of chemotherapy during HCT conditioning. Escalated TBI doses for HCT preparative regimens have led to fewer relapses, but these efforts have typically not translated into improved overall survival (OS) because of increased treatmentrelated mortality [1] [2] [3] . In contrast, the use of radiolabeled monoclonal antibodies (Ab) directed at cell surface antigens allow for the targeted delivery of escalated doses of radiation to bone marrow (BM), spleen, and other sites of malignancy while sparing normal organs [4] [5] [6] [7] [8] [9] [10] [11] . In addition, RIT may improve outcomes when used in combination with chemotherapy and/or HCT [10, [12] [13] [14] . Though leukemia cells express multiple surface antigens that could be targeted, clinical RIT trials to treat AML have primarily used anti-CD33, anti-CD66 and anti-CD45 Ab as vehicles to deliver radiotherapy. CD45 is present on more than 70% of nucleated cells in normal BM, and on more than 85% of leukemic samples [15] [16] [17] , with an average copy number of ,200,000 molecules per cell [18] .
The radionuclides employed in RIT to date have limitations. We have used iodine-131 ( 131 I) in our clinical and pre-clinical studies because there is extensive experience with its medical use, the technology for radiolabeling Abs with iodine is well established, and its gamma component allows direct determination of labeled Ab biodistribution. However, the high-energy gamma component of 131 I requires that patients be treated in radiation isolation, and poses a radiation exposure risk for staff and family. In addition, not all facilitates are capable of handling and disposing of 131 I waste. To supplant 131 I-anti-CD45 Ab an alternative radionuclide yttrium-90 ( 90 Y) has been selected as a therapeutic radioisotope for our studies because it is a pure b-emitter that is commercially available in high specific activity and purity. Moreover, 90 Y has a high-energy tissue penetration. However, 90 Y cannot be imaged directly for which an imaging surrogate for dosimetry studies is required for 90 Y. Therefore, a need remains for alternative radionuclides that can be used for imaging procedures, with adequate energy profiles to achieve therapeutic effects. 
Methods

Mice
Female B6SJLF1/J mice (6 to 12 weeks old) were purchased from Jackson Laboratories (Bar Harbor, ME). Imaging studies used female athymic mice (6 to 12 weeks old) from Harlan Laboratories (Indianapolis, IN). Mice were housed at the FHCRC animal care facility in a pathogen-free environment, and handled by protocols approved by the FHCRC Institutional Animal Care and Use Committee (IACUC IR #1716). This study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Institutes of Health, and all efforts were made to minimize suffering.
Cell Lines, Antibodies and Radiolabeling
Murine AML cells were produced as previously described by serial passage in SJL/J mice [19, 20] . Control Ab (polyclonal rat IgG) was purchased from Sigma Aldrich (St. Louis, MO). Rat IgG2b anti-murine CD45 Ab (30F11) was purified from mouse ascites, and DOTA-30F11 and DOTA-rat IgG were prepared as previously described [21] Y as previously described [22] , and were PD10 column (Bio-Rad, Hercules, CA) purified, resulting in labeling efficiencies for all 90 Y-and 177 Lu-DOTA-Ab injectates of .90%. Radiochemical purity determined by HPLC was .99% for each radiolabeled DOTA-30F11 construct.
Biodistribution Studies
The percent injected dose of radioactivity per gram of tissue (% ID/g) for 90 Y-and 177 Lu-DOTA-30F11, with correction for radioactive decay, were performed in groups of five mice, as previously described [19] .
Cerenkov Imaging
Imaging studies used female athymic mice from Harlan Laboratories (Indianapolis, IN). Radiolabeled DOTA-Ab (0.67 nmol) (100 mCi of either radionuclide) was delivered via tail vein to up to five athymic nude mice at time 50 hours. Mice were anesthetized and imaged with 2.5% isoflurane, using a Xenogen IVIS Spectrum platform from PerkinElmer, Inc. 
Radioimmunotherapy of Leukemic Mice
RIT studies were performed in groups of 10 mice as previously described with 100 or 300 mCi 177 Lu-DOTA-rat IgG [19, 20] . Briefly, mice were placed on a Uniprim-containing diet (irradiated, 4100 ppm; Animal Specialties, Hubbard, OR) 3 days before i.v. injection with 10 5 SJL leukemic cells. Two days later mice received radiolabeled DOTA-30F11 or DOTA-rat IgG. Mice were monitored daily after RIT injections, and weighed 2-3 times per week. Mice were sacrificed in a CO 2 chamber per IACUC protocols for .30% weight loss, for severe lethargy or if significantly moribund.
Radiation Dosimetry
Using biodistribution data and the standard Medical Internal Radiation Dose Methods [23] , radiation absorbed doses for blood and each organ were calculated as described previously [24, 25] .
Toxicity Assessments
Groups of 10 non-leukemia bearing B6SJLF1/J mice were given 300 mCi 90 Y-DOTA-30F11, or 300 or 665 mCi 177 Lu-DOTA-30F11 by tail vein injection. Mice were bled via the retro-orbital plexus at baseline, 1, 2, 3, 4, and 8 weeks after injection of radiolabeled Ab. Five mice per group had blood analyzed for complete blood counts, and the other 5 mice had blood analyzed for kidney and liver function. Values were followed serially and compared to those from untreated age-matched control B6SJLF1/J mice.
Biostatistics
Comparisons were made among groups of 5 mice or 10 mice. Five mice per group provide 80% power to observe a statistically significant difference (at the 2-sided significance level of.05) in a continuous outcome if the true difference between groups is 2.02 standard-deviation units; 10 mice per group provide 80% power if the true difference is 1.33 standard-deviation units. The two-sample t-test was used to compare continuous outcomes, and the log-rank test was used to compare survival between groups. In addition, 95% confidence intervals for the difference between groups were given when comparing the difference between groups.
Results
Comparative Biodistribution Studies
The biodistribution of . These biodistribution data suggest that both radionuclides were effectively targeted to BM and spleen with minor uptake in non-hematologic organs.
To underscore the preferential targeting of hematologic organs compared to normal organs, ratios of the % ID/g of target organs (BM and spleen) to normal organs were calculated for both Fig. 2A) . These ratios were stable or improved with time, presumably due to progressive blood clearance (Fig. 2B) . Spleen-to-normal organ ratios were higher than BM-to-normal organ ratios for both 90 Y and 177 Lu (Fig. 2C and D) , likely due to the higher density of CD45
+ cells in the spleen in this leukemia model. Radiation-sensitive normal organs were relatively spared from excessive radiation exposure, with spleen-to-lung ratios of 18.0:1 and 13 Lu-DOTA-30F11, respectively. In addition, the kidneys, a particular source of concern in radioimmunotherapy studies, showed favorable radiation exposure with BM-to-kidney ratios of 3.0:1 and 3. + emissions travel through an optically transparent insulating material (typically water) with a velocity that exceeds the speed of light. As charged particles travel through water, they lose kinetic energy by polarizing the electrons of water molecules. Relaxation of the polarized molecules occurs via the emission of light energy, giving rise to the observed Cerenkov emission, or a continuous spectrum of light from near-ultraviolet to visible [26] [27] [28] [29] . Athymic nude mice were injected with 300 mCi of either Lu-DOTA-30F11, and both radiolabeled Ab conjugates displayed distinct, focal localization to the spleen by CLI as early as 15 minutes post-injection. The spleens were the major organ of localization in all imaged mice, and the overwhelming splenic pixel intensity could have prevented visualization of other sites of uptake. As expected, imaging confirmed increased uptake in CD45 + organs, especially spleen and liver, for both radionuclides. However, Y had previously been well tolerated by mice from a related SJL strain [19] . All ten untreated control mice died, with the median survival (the time at which the Kaplan-Meier estimate of survival reaches 50% or lower) being 39 days. Eight of the 10 mice that received 100 mCi Y-DOTA-30F11 died with the median survival not reached (Fig 4A) . These data showed a statistically significant trend in decreased mortality as dose increased (from control to 100 mCi to 300 mCi, p.003). On the other hand, all 10 mice that received 100 mCi 177 Lu-DOTA-30F11 died as did all 10 mice that received 300 mCi 177 Lu-DOTA-30F11 (median day of survival, 52 days, 16 days, respectively). There was actually a statistically significant trend for increased mortality as the dose of 177 Lu-DOTA-30F11 increased. To confirm that the therapeutic benefits observed were due to targeting of radionuclides to the BM and spleen and not to a nonspecific radiation effect, mice were also treated with an isotype negative control DOTA-rat IgG that was radiolabeled with 300 mCi of either 90 
Lu
The absence of a therapeutic benefit when using 177 Lu-DOTA-30F11 despite similar targeting specificity of 90 Y-DOTA-30F11 was unexpected. We hypothesized this might be due, at least in part, to differences between absorbed radiation Lu-DOTA-30F11 [23] . Dosimetry calculations showed that the BM absorbed dose per mCi of 90 Y-DOTA-30F11 injected was more than 11-times greater than the absorbed radiation dose delivered by 177 Lu-DOTA-30F11 (8.5 versus 0.74 cGy/mCi; Table 1 ). Although not as dramatic, the spleen absorbed dose per unit injected was more than 2-fold higher for (Fig. 5F ), and ALP (Fig. 5H ) from RIT treated mice did not differ from untreated matched control mice throughout the 8 weeks of monitoring. In summary, toxicity studies showed transient myelotoxicity with anti-CD45 RIT that normalized by 4 weeks after therapy, with minimal hepatic or renal toxicity.
Discussion
The results suggest that 90 Y-anti-CD45 RIT was more effective than 177 Lu-anti-CD45 RIT to treat leukemia in a syngeneic murine model (Fig. 4) . Biodistribution studies showed both Lu-DOTA-30F11 localized similarly to target sites with the highest disease burden, BM and spleen (Fig. 1) . In vivo Cerenkov imaging (Fig. 3) allowed visualization of radiolabeled DOTA-30F11 with both b - [30, 31] . Unfortunately, their decay energies are significantly different such that even if this schema was followed the absolute energy differences may not have allowed for comparable radiation doses. 177 Lu has a low energy gamma-radiation fraction (0.2 MeV) with the majority in the beta range (78.6% at 0.5 MeV) and a mean energy beta-radiation of E mean 50. Lu-DOTA-30F11 may be explained, at least partially, by the large differences in decay energy that lead to disparate absorbed doses of the two radionuclides.
Absorbed doses were lower in 177 Lu-DOTA-30F11 treated mice compared to mice treated with 90 Y-DOTA-30F11 when each group received 300 mCi of radioactivity. However, mice given an equivalent liver absorbed dose (665 mCi of Lu-DOTA-30F11 at a lower dose-rate over its longer half-life. Indeed, clinical trials have shown increased relapse rates with increased dose fractionation and reduced dose-rates [33] [34] [35] . Similarly, murine transplant models that increased dose fractionation or lowered dose-rate of radiation effectively restored host hematopoiesis, and required higher total TBI doses for donor engraftment [36] , suggesting that lower dose-rates may significantly lower the cytotoxic effect of radiation.
Lastly, these results also assessed the potential long-term toxic effects of 90 
Yversus
177
Lu-anti-CD45 RIT. Mice without leukemia used in toxicity studies may explain why mice given 300 mCi 177 Lu-DOTA-30F11 did not display the fatal toxicities that were seen in the RIT studies employing disease-bearing animals. While speculative, leukemic cells used for RIT experiments provided additional CD45 + target, which lead to more radioactivity in hematolymphoid tissues producing more hematologic toxicity. Further, myelotoxicity could have been more pronounced with 177 Lu because the longer half-life interfered with effective hematopoiesis, risking potentially fatal infections, lethal anemia, and/or bleeding complications.
In summary, these studies in a syngeneic disseminated leukemia model confirm the therapeutic efficacy of 90 Y-anti-CD45 RIT for leukemia but do not support the addition of 177 Lu to RIT treatment options. The lack of efficacy using 177 Lu was not due to suboptimal targeting as both radionuclides were delivered equally to BM and spleen, but may have been due to differences in radiation properties, such as decay energies, effective path-lengths, and dose-rates. The longer half-life of 177 Lu was unable to provide a comparable absorbed dose of 90 Y, and in fact its longer half-life and radiation effects may have interfered with effective hematopoiesis and further added to its myelotoxicity.
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